Streetwise Reports' Article Archives — February 2020 back to current month (28)
Sangamo Therapeutics shares traded higher after the company reported Q4/19 and FY/19 earnings and advised that it signed a global collaboration agreement with Biogen to develop gene regulation therapies for Alzheimer's, Parkinson's, neuromuscular and neurological diseases.
Shares of Teladoc Health climbed to a new 52-week high price after the firm reported Q4/19 and FY/19 financial results that included a 32% year-over-year increase in revenue and a 57% increase in patient visits.
Shares of Nemaura Medical traded 20% higher after the firm reported that it is investigating using its non-invasive continuous glucose monitor sugarBEAT® jointly with its planned health subscription service BEAT®diabetes, to provide personalized lifestyle coaching for people with Type 2 diabetes and prediabetes.
Reliq Health Technologies advised that it has been selected as remote patient monitoring and chronic care management solutions partner by U.S. health data company MaxMD.
Shares of Moderna traded 23% higher after the company reported that it has developed and shipped an mRNA vaccine against novel coronavirus for use in a Phase 1 testing study in the U.S.
These events for Axsome Therapeutics are described in an H.C. Wainwright & Co. report.
Shares of NGM Biopharmaceuticals reached a new 52-week intraday high price after the company posted positive topline data from Cohort 4 of its Phase 2 study of aldafermin in NASH Patients.
Avivagen's proprietary product yielded statistically significant results.
Healthcare Tech Firm Lands Contract in Florida (02/22/2020)
Reliq Health Technologies will provide the client with two telehealth platforms.
Tech Firm Announces New Deals Worth $1 Million (02/21/2020)
These newly signed contracts of HealthSpace Data Systems are with governmental agencies in two U.S. states.
Reliq Health Technologies is chosen based on three criteria.
Premier Health Group announced that it changed its name to CloudMD Software & Services Inc., and trading under the symbol DOC will begin Feb. 24.
Shares of Baudax Bio traded more than 20% higher and set a new 52-week high price after reporting that the FDA approved the company's non-opioid ANJESO™ drug for management of moderate to severe pain.
The reasons a green light is anticipated and how it relates to the closing of Avenue Therapeutics' pending acquisition are discussed in an H.C. Wainwright & Co. report.
Fincom Investment Partners profiles TOMI Environmental Solutions, whose SteraMist disinfectant technology kills the coronavirus.
Shares of Viela Bio Inc. rose 20% after an analyst at H.C. Wainwright & Co. initiated coverage of the stock.
This agreement will provide another sales channel and additional revenue opportunities for Avivagen's proprietary product.
Shares of ImmunoGen Inc. reached a new 52-week intraday high price after the company announced FY/19 financial results and reported on recent developments including the completion of a $97.6 million capital raise in January 2020.
Shares of vTv Therapeutics traded 50% higher after the company reported positive results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 used in the treatment of patients with type 1 diabetes.
The events in that trio are presented in a ROTH Capital Partners report.
With the added clients, the company will expand into two more clinical realms.
Shares of Myriad Genetics traded 30% lower after the firm released Q2/20 earnings and announced the appointment of a new interim CEO.
Shares of Cortexyme Inc. traded 20% higher after the company reported that it secured an additional $125M in capital from a private placement. The firm intends to use the proceeds to fund current Alzheimer's clinical trials and ongoing operations.
Shares of Vivus traded higher after the FDA approved the company's supplemental New Drug Application for an improved formulation of PANCREAZE® (pancrelipase) for use in the treatment of exocrine pancreatic insufficiency due to cystic fibrosis and other conditions.
Understanding Fortress Biotech (02/05/2020)
Daniel Carlson of Tailwinds Research takes a close look at what he calls a "great value opportunity," with a focus on subsidiary Avenue Therapeutics.
The product is initially available to residents of British Columbia.
The appointed physician will be tasked with developing global business for the company.
Insmed Inc.'s shares traded higher today after the company reported positive top-line results from its Phase 2 WILLOW Study of INS1007 in patients with non-cystic fibrosis bronchiectasis.
|"Experiments showed that PMN's PMN310 has a unique binding profile."|